Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Dihydroartemisinin-piperaquine + sulfadoxine-pyrimethamine for sickle cell anemia
PACTR202507605302954Phase 3Recruiting
- Sponsor
- Thrasher Research Fund
- Start
- Jul 2025
- Modality
- Classical Binding Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules, Nucleic Acid-Directed Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3 trial of dihydroartemisinin, piperaquine, sulfadoxine and pyrimethamine in malaria and sickle cell anemia (SCA), sponsored by Thrasher Research Fund. Started Jul 2025; status: recruiting.
02
Drugs
dihydroartemisininpiperaquinesulfadoxinepyrimethamine
03
Conditions
malariasickle cell anemia (SCA)
Beyond the preview
Go deeper on PACTR202507605302954.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on PACTR202507605302954.